(MedPage Today) — A secondary analysis of the phase III VISION trial presented at this year’s American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway inhibitors (ARPIs) to ¹…
Source link : https://www.medpagetoday.com/meetingcoverage/gucsvideopearls/114748
Author :
Publish date : 2025-03-20 15:31:00
Copyright for syndicated content belongs to the linked Source.
